Small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
作者信息
Dingemans A-M C, Früh M, Ardizzoni A, Besse B, Faivre-Finn C, Hendriks L E, Lantuejoul S, Peters S, Reguart N, Rudin C M, De Ruysscher D, Van Schil P E, Vansteenkiste J, Reck M
机构信息
Department of Pulmonology, Erasmus Medical Center, Rotterdam, The Netherlands; Department of Pulmonology, GROW School for Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht, The Netherlands.
Department of Oncology and Haematology, Kantonsspital St. Gallen, St. Gallen, Switzerland; Department of Medical Oncology, University of Bern, Bern, Switzerland.
出版信息
Ann Oncol. 2021 Jul;32(7):839-853. doi: 10.1016/j.annonc.2021.03.207. Epub 2021 Apr 20.
Abstract
摘要
相似文献
1
Small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.小细胞肺癌：ESMO 诊断、治疗及随访临床实践指南
Ann Oncol. 2021 Jul;32(7):839-853. doi: 10.1016/j.annonc.2021.03.207. Epub 2021 Apr 20.
2
Small-cell lung cancer (SCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.小细胞肺癌（SCLC）：ESMO诊断、治疗及随访临床实践指南
Ann Oncol. 2013 Oct;24 Suppl 6:vi99-105. doi: 10.1093/annonc/mdt178. Epub 2013 Jun 27.
3
Small-cell lung cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up.小细胞肺癌：欧洲肿瘤内科学会关于诊断、治疗及随访的临床建议
Ann Oncol. 2009 May;20 Suppl 4:71-2. doi: 10.1093/annonc/mdp133.
4
Small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.小细胞肺癌：欧洲肿瘤内科学会临床实践指南之诊断、治疗及随访
Ann Oncol. 2010 May;21 Suppl 5:v120-5. doi: 10.1093/annonc/mdq172.
5
Looking ahead to new therapies in small cell lung cancer.展望小细胞肺癌的新疗法。
Clin Adv Hematol Oncol. 2018 Apr;16(4):269-272.
6
Lung Cancer OncoGuia.肺癌诊疗指南
Clin Transl Oncol. 2009 Dec;11(12):805-24. doi: 10.1007/s12094-009-0449-0.
7
Small cell lung cancer. Clinical practice guidelines in oncology.小细胞肺癌。肿瘤学临床实践指南。
J Natl Compr Canc Netw. 2004 Mar;2(2):134-57. doi: 10.6004/jnccn.2004.0012.
8
Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.早期和局部晚期非小细胞肺癌（NSCLC）：ESMO临床实践指南之诊断、治疗及随访
Ann Oncol. 2013 Oct;24 Suppl 6:vi89-98. doi: 10.1093/annonc/mdt241. Epub 2013 Jul 16.
9
Lung cancer.肺癌。
Lancet. 2021 Aug 7;398(10299):535-554. doi: 10.1016/S0140-6736(21)00312-3. Epub 2021 Jul 21.
10
Timeliness of lung cancer diagnosis and treatment: a single-center experience.肺癌诊断与治疗的及时性：单中心经验
Asian Cardiovasc Thorac Ann. 2019 Oct;27(8):670-676. doi: 10.1177/0218492319881036. Epub 2019 Sep 30.
引用本文的文献
1
Current and Emerging Therapeutic Strategies for Limited- and Extensive-Stage Small-Cell Lung Cancer.局限期和广泛期小细胞肺癌的当前及新出现的治疗策略
Med Sci (Basel). 2025 Aug 18;13(3):142. doi: 10.3390/medsci13030142.
2
Recent Advances in PET and Radioligand Therapy for Lung Cancer: FDG and FAP.肺癌正电子发射断层显像（PET）及放射性配体疗法的最新进展：氟代脱氧葡萄糖（FDG）与成纤维细胞活化蛋白（FAP）
Cancers (Basel). 2025 Aug 1;17(15):2549. doi: 10.3390/cancers17152549.
3
Innovative diagnostic approaches for lung cancer: integrating traditional cytology with qPCR for rapid and reliable results.肺癌的创新诊断方法：将传统细胞学与定量聚合酶链反应相结合以获得快速可靠的结果。
Sci Rep. 2025 Aug 8;15(1):29085. doi: 10.1038/s41598-025-13743-4.
4
Immune-Checkpoint Inhibitors in Lung Neuroendocrine Tumors - A Systematic Review and Meta-Analysis.肺神经内分泌肿瘤中的免疫检查点抑制剂——一项系统评价与荟萃分析
Onco Targets Ther. 2025 Jul 31;18:833-843. doi: 10.2147/OTT.S515194. eCollection 2025.
5
Re-thinking the Role of Thoracic Radiotherapy in the First-Line Treatment for Extensive-Stage Small Cell Lung Cancer.重新审视胸部放疗在广泛期小细胞肺癌一线治疗中的作用
Curr Treat Options Oncol. 2025 Aug;26(8):764-774. doi: 10.1007/s11864-025-01342-4. Epub 2025 Jul 31.
6
Role of prophylactic cranial irradiation in patients with limited disease small cell lung cancer: A Danish single institution cohort.预防性颅脑照射在局限性疾病小细胞肺癌患者中的作用：一项丹麦单机构队列研究。
Acta Oncol. 2025 Jul 25;64:966-971. doi: 10.2340/1651-226X.2025.43935.
7
Eosinopenia predicts poor outcomes in patients with lung cancer with the omicron variant of COVID-19.嗜酸性粒细胞减少预示着感染新冠病毒奥密克戎变异株的肺癌患者预后不良。
Front Med (Lausanne). 2025 Jul 9;12:1583843. doi: 10.3389/fmed.2025.1583843. eCollection 2025.
8
[F]FDG PET/CT in the Preoperative Diagnostic and Staging of Lung Cancer-A Pictorial Evaluation.[F]氟代脱氧葡萄糖正电子发射断层扫描/计算机断层扫描在肺癌术前诊断及分期中的应用——影像评估
J Clin Med. 2025 Jun 23;14(13):4449. doi: 10.3390/jcm14134449.
9
Redefining the Fight Against SCLC: Standards, Innovations, and New Horizons.重新定义抗击小细胞肺癌的斗争：标准、创新与新视野
Cancers (Basel). 2025 Jul 7;17(13):2256. doi: 10.3390/cancers17132256.
10
The combination of chemotherapy and immune checkpoint inhibitors in recurrent extensive-stage small cell lung cancer: a case report.复发性广泛期小细胞肺癌中化疗与免疫检查点抑制剂联合应用：一例报告
J Cardiothorac Surg. 2025 Jul 5;20(1):286. doi: 10.1186/s13019-025-03513-8.
本文引用的文献
1
Safety of G-CSF with concurrent chemo-radiotherapy in limited-stage small cell lung cancer - Secondary analysis of the randomised phase 3 CONVERT trial.粒细胞集落刺激因子（G-CSF）联合放化疗用于局限期小细胞肺癌的安全性——随机3期CONVERT试验的二次分析
Lung Cancer. 2021 Mar;153:165-170. doi: 10.1016/j.lungcan.2021.01.025. Epub 2021 Jan 30.
2
Second-line nivolumab in relapsed small-cell lung cancer: CheckMate 331.二线纳武利尤单抗治疗复发小细胞肺癌：CheckMate 331 研究。
Ann Oncol. 2021 May;32(5):631-641. doi: 10.1016/j.annonc.2021.01.071. Epub 2021 Feb 1.
3
Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133).阿替利珠单抗联合卡铂和依托泊苷治疗广泛期小细胞肺癌患者的总生存更新和 PD-L1 亚组分析（IMpower133）。
J Clin Oncol. 2021 Feb 20;39(6):619-630. doi: 10.1200/JCO.20.01055. Epub 2021 Jan 13.
4
Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial.度伐利尤单抗联合或不联合 Tremelimumab 与单用依托泊苷联合顺铂一线治疗广泛期小细胞肺癌（CASPIAN）：一项随机、对照、开放标签、3 期临床试验的更新结果。
Lancet Oncol. 2021 Jan;22(1):51-65. doi: 10.1016/S1470-2045(20)30539-8. Epub 2020 Dec 4.
5
Patient-reported outcomes with first-line durvalumab plus platinum-etoposide versus platinum-etoposide in extensive-stage small-cell lung cancer (CASPIAN): a randomized, controlled, open-label, phase III study.度伐利尤单抗联合铂类-依托泊苷与铂类-依托泊苷一线治疗广泛期小细胞肺癌的患者报告结局（CASPIAN）：一项随机、对照、开放标签的III期研究。
Lung Cancer. 2020 Nov;149:46-52. doi: 10.1016/j.lungcan.2020.09.003. Epub 2020 Sep 10.
6
Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study.帕博利珠单抗治疗的晚期实体瘤患者肿瘤突变负荷与结局的相关性：多队列、开放标签、Ⅱ期 KEYNOTE-158 研究的前瞻性生物标志物分析。
Lancet Oncol. 2020 Oct;21(10):1353-1365. doi: 10.1016/S1470-2045(20)30445-9. Epub 2020 Sep 10.
7
Carboplatin plus etoposide versus topotecan as second-line treatment for patients with sensitive relapsed small-cell lung cancer: an open-label, multicentre, randomised, phase 3 trial.卡铂联合依托泊苷与拓扑替康二线治疗敏感复发性小细胞肺癌的疗效比较：一项开放标签、多中心、随机、III 期临床试验。
Lancet Oncol. 2020 Sep;21(9):1224-1233. doi: 10.1016/S1470-2045(20)30461-7.
8
Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study.帕博利珠单抗或安慰剂联合依托泊苷和铂类药物作为广泛期小细胞肺癌一线治疗：随机、双盲、III 期 KEYNOTE-604 研究。
J Clin Oncol. 2020 Jul 20;38(21):2369-2379. doi: 10.1200/JCO.20.00793. Epub 2020 May 29.
9
Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial.鲁比卡丁作为小细胞肺癌二线治疗药物的疗效：一项单臂、开放标签、2 期篮子试验。
Lancet Oncol. 2020 May;21(5):645-654. doi: 10.1016/S1470-2045(20)30068-1. Epub 2020 Mar 27.
10
Impact of F-FDG PET/CT in Staging Patients With Small Cell Lung Cancer: A Systematic Review and Meta-Analysis.F-FDG PET/CT 在小细胞肺癌患者分期中的作用：一项系统评价和荟萃分析
Front Med (Lausanne). 2020 Jan 29;6:336. doi: 10.3389/fmed.2019.00336. eCollection 2019.
Zotero 插件